101 Therapeutics Releases Clinical Evidence Package for Macrophage-Targeted 101-PGC-005 and Seeks Urgent Independent Review for Bundibugyo Ebola Disease

101 Therapeutics has made an audacious, almost unprecedented move: publicly releasing its full clinical evidence package for 101-PGC-005, a macrophage-targeted dexamethasone prodrug, and demanding urgent independent review for the escalating Bundibugyo Ebola outbreak in Central Africa. This bypasses traditional scientific peer review timelines, directly challenging regulators and global health bodies to accelerate evaluation of a potential therapeutic for a deadly virus with no approved treatments amidst a declared Public Health Emergency of International Concern. The stakes are immense. The current Bundibugyo Ebola Disease (BVD) outbreak, centered in the Democratic Republic of the Congo and Uganda, has surged to over 900 confirmed cases and more than 230 deaths since May 2026, with the true toll likely far higher due to conflict and surveillance gaps. Unlike the more common Zaire Ebola, effective vaccines and treatments for BVD remain elusive, leaving supportive care as the only option. 101-PGC-005, which demonstrated superiority over standard dexamethasone in Phase II/III trials for severe COVID-19-associated inflammation, targets the pathogenic CD206-positive macrophages implicated in severe viral cytokine storm, aiming to temper the body's overzealous immune response without broad immunosuppression. Dr. Michael Goldberg, 101 Therapeutics' Founder and CSO, argues the active outbreak necessitates accelerated scrutiny, not waived standards. The company is now pressuring international bodies like the WHO, national regulators in affected countries, and potential partners to leverage emergency frameworks such as MEURI for rapid assessment and potential deployment. Whether this high-stakes gamble will fast-track a critically needed therapeutic to the front lines or expose the dangers of accelerated review without full peer validation remains the urgent question.